



Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase

Journal:	<i>Journal of Investigative Dermatology</i>
Manuscript ID:	draft
Manuscript Type:	Original Article
Date Submitted by the Author:	
Complete List of Authors:	Abu Ubeid, Anan; elixir institute of regenerative medicine, Translational research Zhao, Longmei; elixir institute of regenerative medicine, Translational research Wang, Ying; elixir institute of regenerative medicine, Translational research Hantash, Basil; Stanford University, Surgery
Key Words:	Tyrosinase, hyperpigmentation, inhibition, melanocytes, oligopeptide

1
2
3 **Title:** Short-sequence oligopeptides with inhibitory activity against mushroom and human
4 tyrosinase
5
6

7
8 **Short title:** Oligopeptide tyrosinase inhibitors
9

10 **Authors:** Anan Abu Ubeid, BS^{1,2}, Longmei Zhao, MD, PhD^{1,2}, Ying Wang, PhD^{1,2}, Basil M.
11 Hantash, MD, PhD¹
12

13
14
15
16 ¹Elixir Institute of Regenerative Medicine, San Jose, CA
17

18
19 ²These authors contributed equally to this manuscript
20

21
22 **Corresponding Author:** Basil M. Hantash, MD, PhD
23

24
25 **Contact Information:** Elixir Institute of Regenerative Medicine
26

27 5941 Optical Court
28

29 San Jose, CA 95138
30

31 Phone No.: (323) 306-4330
32

33 Fax No.: (323) 306-4330
34

35 E-mail: basil@elixirinstitute.org
36
37
38

39 **Funding sources:** None.
40

41
42 **Disclosure statement:** None.
43

44
45 **Prior Presentation:** None.
46

47
48 **Word Count:** 3743.
49

50
51 **Abbreviations:** [E] = enzyme concentration; HQ = hydroquinone; [I] = inhibitor; PIH = post-
52 inflammatory hyperpigmentation; [S] = substrate; UV = ultraviolet.
53
54
55
56
57
58
59
60

Abstract

Cutaneous hyperpigmentation is a common disorder due to excess melanin production by the enzyme tyrosinase. The gold standard for treatment is hydroquinone (HQ), which reduces pigmentation through its toxicity to melanocytes rather tyrosinase inhibition. We screened an internal library for oligopeptides that inhibited both mushroom and human tyrosinase but demonstrated no cytotoxicity to human melanocytes. We identified two highly active inhibitory sequences, P3 and P4, of 8 and 10 amino acid length, respectively. Mushroom tyrosinase inhibition was dose-dependent with IC₅₀ values of 123 and 40 μ M, respectively, compared to 680 μ M for HQ. Other oligopeptides demonstrated weaker or no inhibitory activity. Kinetic studies revealed that P3 and P4 are competitive inhibitors of mushroom tyrosinase. At 100 μ M, P3 and P4 inhibited human tyrosinase by 25 to 35%. This inhibition partially depended on whether L-dopa or L-tyrosine was the substrate, suggesting that tyrosinase may contain contains two distinct catalytic sites. Treatment of melanocytes with 100 μ M P3 or P4 for 7 days led to a 27% or 43% reduction in melanin content, respectively. This inhibition was independent of cell proliferation and cytotoxic effects. Our data suggest that peptide-mediated inhibition of melanogenesis is due to reduction of tyrosinase activity.

Keywords

Tyrosinase, hyperpigmentation, inhibition, melanocytes, oligopeptide, skin-whitening agent.

Introduction

Melanin, the end product of melanogenesis, determines the color of human skin, hair, and eyes and is synthesized within unique membrane bound organelles called melanosomes. The type and amount of melanin and its distribution pattern in the surrounding keratinocytes determine the actual color of skin (Parvez, Kang et al. 2006). Melanogenesis is regulated by a variety of environmental, hormonal, and genetic factors, such as ultraviolet (UV) exposure, α -melanocyte-stimulating hormone, melanocortin 1 receptor, and agouti-related protein (Petit and Pierard 2003);(Kadokaro, Kanto et al. 2003). The functions of melanin include protection of skin from UV radiation, the inhibition of photocarcinogenesis, and the synthesis of vitamin D₃ (Lindquist 1973). Hyperpigmentation is a very common and usually harmless disorder in which patches of skin become darker in color than the normal surrounding skin. This darkening occurs when an excess of melanin is formed and deposited in the skin. The most common pigmentation disorders for which patients seek treatment are melasma and post-inflammatory hyperpigmentation (PIH) (Lynde, Kraft et al. 2006). These conditions may have a major impact on a person's psychological and social well-being, contributing to lower productivity, social functioning, and self-esteem (Finlay 1997).

Melasma is an acquired pigmentary disorder that occurs in women of all racial and ethnic groups (Rendon, Berneburg et al. 2006). While the cause of melasma is unknown, factors include: genetic predisposition, UV light exposure, and estrogen (Johnston, Sviland et al. 1998). PIH represents a pathophysiologic response to cutaneous inflammation, such as acne, atopic dermatitis, lichen planus, chronic dermatitis, and photo toxic eruptions (allergic reactions to drugs coupled with exposure to sunlight) (Lacz, Vafaie et al. 2004). Tyrosinase is a multi-functional copper containing oxidase, and is considered the key enzyme orchestrating mammalian melanogenesis (Sanchez-Ferrer, Rodriguez-Lopez et al. 1995). This key enzyme

1
2
3 catalyzes two distinct reactions in the biosynthesis pathway of melanin: the hydroxylation of a
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
catalyzes two distinct reactions in the biosynthesis pathway of melanin: the hydroxylation of a
monophenol (tyrosine) and the conversion of an o-diphenol (dopa) to the corresponding o-
quinone (dopaquinone). A multitude of different tyrosinase inhibitors are used today to treat
epidermal hyperpigmentation conditions. Skin-whitening agents in the cosmetics industry include
hydroquinone (Jimbow, Obata et al. 1974), arbutin (Maeda and Fukuda 1996), kojic acid
(Cabanes, Chazarra et al. 1994), vitamin C (Kojima, Yamaguchi et al. 1995), retinol (Pathak,
Fitzpatrick et al. 1986), azelaic acid (Schallreuter and Wood 1990), and other botanicals.

The most popular depigmenting agent, hydroquinone (dihydroxybenzene; HQ), has been in use
since 1961. HQ, with formulations of 2%–4%, has been widely used for melasma treatment and
reports of its clinical efficacy have been well documented (Ennes, Paschoalick et al. 2000). HQ
inhibits the conversion of dopa to melanin by inhibiting the activity of tyrosinase (Palumbo,
d'Iscia et al. 1991). In addition to tyrosinase inhibition, Penney et al. suggested that HQ exerts
its effect on melanogenesis through degradation of melanosomes, and destruction of
melanocytes (Penney, Smith et al. 1984). It was also found that alteration of melanosome
functions, depletion of glutathione, generation of reactive oxygen species and subsequent
oxidative damage of membrane lipids and proteins may play a role in the depigmenting effect of
HQ (Briganti, Camera et al. 2003). HQ is considered to be cytotoxic to melanocytes, potentially
mutagenic to mammalian cells (Curto, Kwong et al. 1999), and causes skin irritation (Parvez,
Kang et al. 2006). Due to the long-term risk of mutagenesis, (DeCaprio 1999), the use of HQ in
cosmetics has been banned by the European Committee (24th Dir. 2000/6/EC) and
formulations of 4% or greater are available only by prescription in selected other countries
(Solano, Briganti et al. 2006).

This has led to the use of alternative agents such as kojic acid and arbutin. However, these agents
failed to demonstrate efficacy in vivo, as clinical trials have been disappointing to date (Curto,

1
2
3 Kwong et al. 1999). The effectiveness of these products appears to be limited due to their
4
5 adverse effects, poor skin penetrations, and low formulation stabilities (Hermanns, Pierard-
6
7 Franchimont et al. 2000). More recently, investigators have turned their attention to short-
8
9 sequence peptides as potential therapeutic candidates for the treatment of skin disorders. The
10
11 most widely studied and popular signal peptide is the sequence lysine-threonine-threonine-lysine-
12
13 serine (KTTKS) found on type-I procollagen (Katayama, Armendariz-Borunda et al. 1993). This
14
15 pentapeptide has been demonstrated to stimulate feedback regulation of new collagen synthesis
16
17 and to result in an increased production of extracellular matrix proteins such as types I and II
18
19 collagen and fibronectin, significantly improving photoaged human facial skin (Robinson,
20
21 Fitzgerald et al. 2005; Lupo and Cole 2007).
22
23
24
25
26
27
28

29 In the present study, we screened an internal oligopeptide library for inhibitory activity against
30
31 tyrosinase and absence of melanocyte toxicity. We discovered several short-sequence peptides
32
33 which met both these criteria.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Inhibition of mushroom tyrosinase by oligopeptides

As the rate-limiting enzyme in melanin production, tyrosinase was targeted during the screening of seven potential hypopigmenting agents (table 1). Of these oligopeptides, two showed substantial inhibitory effects on mushroom and human tyrosinase activity, whereas the other peptides had either poor or no inhibitory activity on tyrosinase. Dose-response curves were obtained after an incubation time of 120 min (Fig. 1). Peptide P6 had no effect on tyrosinase activity, whereas peptides P1, P2, P5 and P7 showed an inhibitory effect at high concentrations. On the other hand, peptides P3 and P4 showed very impressive inhibition at relatively low concentrations. The IC₅₀ for P3 and P4 was 123 μ M and 40 μ M respectively, compared to 680 μ M for HQ. Figure 1 also illustrates that the inhibitory activity of the peptides was dose-dependent, with P4 showing inhibitory activity at concentrations as low as 50 μ M. Based on the above results, we focused our attention on peptides P3 and P4. Figure 2 shows the time response curves and indicates that P3 and P4 exhibited similar inhibitory activity as HQ. Moreover, peptide P4 showed a more potent inhibitory effect at concentrations as low as 50 μ M.

Kinetics of mushroom tyrosinase inhibition by oligopeptides

We next determined the kinetics of the inhibition for P3, P4, and HQ using a standard assay (Pomerantz 1966). The inhibition mechanisms of the two peptides P3 and P4, as well as that of HQ, are all competitive as demonstrated by Lineweaver-Burke plots in figure-3. The double reciprocal plots illustrate that V_{max} was independent of substrate concentration for all three inhibitors, whereas the K_m was altered. The inhibition constant (K_i) for HQ, P3 and P4 was determined to be 0.053, 0.048 and 0.070 mM, respectively.

Inhibition of human tyrosinase by oligopeptides

We also examined the inhibitory activity of P3 and P4 relative to HQ against human tyrosinase under two settings: the first using L-dopa as the substrate, and the second using L-tyrosine as the substrate with L-dopa as co-factor. In the latter, L-dopa acts as a hydrogen donor helping eliminate the lag period observed during tyrosine hydroxylation (Pomerantz and Warner 1967). Figure 4 shows dose-dependent inhibition for P3, P4 and HQ. It can be seen that P3 and P4 are more potent than HQ at concentrations as low as 30 μ M. At 100 μ M, human tyrosinase activity was reduced by 35% for P4 and 25% for P3. With L-dopa as the substrate, P3 was more potent than P4 at inhibiting the enzyme. On the other hand, when L-tyrosine was used as the substrate, P4 showed stronger inhibition than P3. These data support the hypothesis that tyrosinase has two distinct catalytic sites for L-dopa and L-tyrosine (Olivares, Jimenez-Cervantes et al. 2001).

Effects of HQ, P3 and P4 on melanin content of melanocytes

To determine the effect of the oligopeptides on melanogenesis, we incubated melanocytes with HQ, P3, or P4 for 1 week and then measured melanin content. At a concentration of 10 μ M, HQ, P3, and P4 reduced melanin content by $7 \pm 2\%$, $22 \pm 1\%$ and $40 \pm 1\%$, respectively (Fig. 5). At 100 μ M, P3 and P4 reduced melanin content by $27 \pm 2\%$ and $43 \pm 2\%$, respectively, while HQ was found to be 100% toxic to melanocytes.

Cytotoxic and proliferative effects of HQ, P3 and P4 on melanocytes

To exclude the possibility that P3 and P4 were reducing melanin content by inhibiting cell proliferation or inducing cytotoxicity, melanocytes were incubated in the presence or absence of various concentrations of HQ, P3, or P4, and proliferation assessed at various time points using the WST-1 cell proliferation kit. Figure 6 shows that treatment with 100 μ M or greater of HQ completely abolished WST-1 activity (from 0.45 ± 0.02 at day 1 down to 0.0 at day 5). These data are consistent with our above findings and imply that HQ is cytotoxic to melanocytes at these

1
2
3 concentrations. Unlike HQ, 10 μ M, 100 μ M, or 1 mM P3 did not alter melanocyte proliferation
4 rates relative to the control group. Although no effect on melanocytes proliferation was
5 observed for P4 at 10 and 100 μ M after 5 days of incubation, proliferation was inhibited by $10 \pm$
6
7
8
9
10 2% at a concentration of 1 mM.
11

12
13
14
15 Table 2 further supports our findings regarding the toxicity of HQ on melanocytes compared to
16 peptides P3 and P4. After a 24 hr incubation of melanocytes with 10 μ M HQ, viability staining
17 with trypan blue indicated that 27% of cells were dead. This was one order of magnitude greater
18 than that for P4. The toxic effects of HQ were dose-dependent and at concentrations of 30 and
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
100 μ M, 41 and 98% of melanocytes were no longer viable, respectively. The highest rate of cell
death for P4 was 18% after incubating the melanocytes with 1 mM of P4 for six days. At
concentrations greater than 100 μ M for HQ there was 100% cell death starting within 24 hrs of
exposure. P3 was found to be considerably less toxic to melanocytes even at concentrations as
high as 1 mM (2% cell death after six days).

Discussion

In this study, we screened an internal library for oligopeptides with inhibitory activity against mushroom and human tyrosinase. Even though the amino acid sequence similarity between mushroom and human tyrosinase is only 23%, our initial experiments were performed using mushroom tyrosinase since previous studies suggested a strong correlation of efficacy with agents tested against the human form (Sugimoto, Nishimura et al. 2003). The dose and time response curves (Figs. 1 & 2) of these peptides showed that P3 and P4 were 6- and 17-fold more potent inhibitors of mushroom tyrosinase than HQ (IC₅₀ values presented in table 1). Based on this initial screen, we decided to further evaluate and characterize the effects of P3 and P4.

To determine the mode of inhibition, we performed Lineweaver Burk plots of P3 and P4 and compared the kinetics to those of HQ. These studies revealed that similar to HQ, P3 and P4 were competitive inhibitors of tyrosinase. Peptides P3 and P4 were also tested against fresh extracts of human tyrosinase. At a concentration of 100 μ M, the peptides were able to inhibit human tyrosinase activity by 25% to 35%. Although the potency against human tyrosinase appeared reduced relative to that observed with mushroom tyrosinase, several experimental conditions may account for this discrepancy. First, the assay was performed on extracts from lysed melanocytes and not purified human tyrosinase. Although protease inhibitors were included to reduce degradation of human tyrosinase, we did not optimize these conditions. Second, the catalytic site of the extracted human tyrosinase can exist in different redox states than the purified form.

We observed a lengthy lag period for tyrosine oxidation. The oxidation of L-tyrosine by tyrosinase has previously been distinguished by a lag period that is affected by enzyme and substrate concentration, pH, and hydrogen donors such as L-dopa (Pomerantz and Warner 1967). Therefore, when L-tyrosine was the substrate, L-dopa was added as a co-factor at low

1
2
3 micromolar levels to eliminate this lag period. The ability to act as substrate requires a free
4
5 electron donor group, while competitive inhibition, on the contrary, requires the presence of
6
7 powerful electron acceptor groups (Passi and Nazzaro-Porro 1981). These experiments also
8
9 unexpectedly revealed that P3 inhibited human tyrosinase more potently in the presence of L-
10
11 dopa than L-tyrosine, whereas P4 showed greater inhibition in the presence of L-tyrosine as the
12
13 substrate. Hearing et al proposed that there are two catalytic sites on tyrosinase, one for tyrosine
14
15 hydroxylase and another site specific for dopa oxidase activity (Hearing and Ekel 1976). Our
16
17 findings with P3 and P4 further support the hypothesis of separate catalytic sites for L-dopa and
18
19 L-tyrosine (Schallreuter, Kothari et al. 2008).
20
21
22
23
24
25

26
27 Despite the fact that little is known about the effect of short sequence peptides on
28
29 melanogenesis and tyrosinase inhibition, there is great potential for these agents to replace more
30
31 toxic drugs such as HQ, since they are comprised of naturally occurring amino acids that are
32
33 easily metabolized in skin. Therefore, risks of systemic absorption and liver related mutagenesis
34
35 may be avoided during the chronic treatment of hyperpigmentation disorders. Some amino acids
36
37 such L-alanine, glycine, L-isoleucine and L-leucine have previously been shown to possess
38
39 beneficial effects towards disruption of melanogenesis (Ishikawa, Kawase et al. 2007). Ishikawa
40
41 et al reported that a combination of these four amino acids had an additive effect on
42
43 hypopigmentation similar to that of kojic acid. Schurink et al proposed that the peptide should
44
45 contain one or more arginine residues for strong tyrosinase inhibitory and binding
46
47 activity.(Schurink, van Berkel et al. 2007). Moreover, their studies indicated that tyrosinase
48
49 inhibition is optimal when arginine and/or phenylalanine is/are combined with hydrophobic
50
51 aliphatic residues such as valine, alanine or leucine. Besides hydrophobic residues, peptides
52
53 containing the polar, uncharged residues cysteine and serine also demonstrated significant
54
55 inhibitory activity.
56
57
58
59
60

1
2
3 The amino acid tyrosine contains a phenol group, which makes it unique in that it can serve as a
4 substrate or a competitive inhibitor. Oligopeptide P3 contains the combination Arg-Ala in
5 positions 1/2 and 5/6 as well as the amino acids serine and cysteine at positions 4 and 8
6 respectively. The presence of these key residues may explain the strong inhibitory activity
7 observed for P3. For P4, the presence of tyrosine at positions 1 and 10, arginine at positions 2
8 and 4, and serine at 3, 7 and 8 may explain the robust inhibition observed for this oligopeptide.
9
10
11
12
13
14
15
16
17
18

19 One of the main advantages of oligopeptides P3 and P4 is the relative absence of melanocyte
20 cytotoxicity (table 2). While HQ was 100% toxic after a 24-hour treatment at 100 μ M, P3
21 showed no toxic effects after six days of treatment. P4 also showed minimal (7%; table 2)
22 toxicity after the same incubation period. Treatment with 1 mM P3 resulted in a 2% toxicity rate
23 (table 2) and no effect on melanocyte proliferation (Fig. 6). At a concentration 25-fold higher
24 than its IC₅₀ value, P4 began to show mild (18%; table 2) melanocyte toxicity after a prolonged
25 incubation of 6 days. We also confirmed these findings using proliferation assays which revealed
26 that HQ was toxic to melanocytes at concentrations as low as 30 μ M (data now shown), whereas
27 mild reduction of proliferation was first noted only after 3 days of incubation with 1 mM P4
28 (Fig. 6). Lower concentrations did not show any effect on melanocyte proliferation even after
29 prolonged incubation for 5 days, whereas HQ dramatically reduced melanocyte proliferation
30 within 24 hours at concentrations as low as 30 (data not shown) and 100 μ M (Fig. 6).
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 In conclusion, our findings suggest that oligopeptides P3 and P4 may be ideal tyrosinase
51 inhibitors due to their potent enzymatic inhibitory activity, relative absence of melanocyte
52 toxicity, and minimal effects on melanocyte proliferation rates. Further studies are underway to
53 optimize cell penetration and oligopeptide stability for transdermal applications. We believe our
54 novel oligopeptides may hold significant therapeutic potential for the treatment of skin
55 hyperpigmentation disorders. Since both oligopeptides demonstrated substantially improved
56
57
58
59
60

1
2
3 potency against tyrosinase with minimal melanocyte toxicity, clinical use of these agents may
4
5 obviate the need for HQ which derives its primary skin lightening capability via its cytotoxic
6
7 activity.
8
9

10 11 12 13 14 15 16 17 18 19 20 21 22 **Materials and Methods**

23 *Materials*

24
25
26 Mushroom tyrosinase, L-tyrosine, HQ and L-dopa were purchased from Sigma Aldrich. The
27
28 peptides (table 1) were synthesized by NeomPS, Inc (San Diego, California, USA) using solid-
29
30 phase Fmoc chemistry.
31
32

33 34 35 *Enzymatic assay of mushroom tyrosinase*

36
37
38 Tyrosinase inhibition activity was determined *in vitro* using L-tyrosine as the substrate using a
39
40 modified method from Piao *et al* (Piao, Park et al. 2002). The concentration of enzyme, substrate
41
42 and inhibitor was denoted as [E], [S] and [I], respectively. The experiment was conducted in a 96-
43
44 well flat bottom plate. Each well contained 80 μ l of 0.067 M potassium phosphate buffer (pH
45
46 6.8), 40 μ l of 5 mg/ml L-tyrosine dissolved in 0.067 M potassium phosphate buffer (pH 6.8), 40
47
48 μ l of the different concentrations of inhibitor in 5% DMSO solution, and 40 μ l of 480 units/ml
49
50 mushroom tyrosinase solution. The final volume of each well was 200 μ l, containing 1 mg/ml
51
52 [S], 96 units/ml [E] and varying concentrations of [I], ranging from 1 μ M to 10 mM. For the
53
54 negative control wells, the inhibitors were substituted with 5% DMSO solution and adjusted to
55
56 the total volume of 200 μ l. HQ served as the positive control in our experiments. HQ was tested
57
58 in parallel with the oligopeptides at the same concentrations and same conditions. The assay
59
60

1
2
3 mixture was incubated at 37 °C. The optical density of the reaction mixtures, which correlates
4
5 with the amount of dopachrome produced, was measured using a spectrophotometer
6
7 (Varioskan, Thermo Electron Corporation) at 475 nm and at different time periods.
8
9

10 11 12 *Kinetic studies*

13
14 The Lineweaver-Burk plot method was used to determine the reaction kinetics (Burk,
15
16 Lineweaver et al. 1934). Experiments were conducted using the same protocol used for
17
18 measuring mushroom tyrosinase activity except for changes in concentration of [E], [S] and [I].
19
20 [E] was 24 units/ml. The series of [S] were 0.05 (or 0.07 for peptide inhibitors), 0.1, 0.15 and 0.2
21
22 mg/ml. The series of [I] were 0, 0.01 and 0.02 mM, respectively. The results were analyzed
23
24 according to the Lineweaver-Burk plot method that facilitated the determination of the Michaelis
25
26 constant (K_m) and maximum velocity (V_m).
27
28
29
30
31
32

33 34 *Melanin content measurement*

35
36 Melanin content of the melanocytes was measured according to the method of Naeyaert et al
37
38 (Naeyaert, Eller et al. 1991). Human melanocytes were cultured in 24-well plates and treated with
39
40 individual test samples for 7 days. P3, P4, and HQ were tested at 10 and 100 μ M each, all in
41
42 triplicate. Media was changed every other day and fresh oligopeptide or HQ was added. After
43
44 seven days, the media was discarded and the wells were washed with PBS. Cells were detached
45
46 by short incubation in trypsin/EDTA (0.25%/0.1 % in PBS). An aliquot was used for cell
47
48 counting and the remaining cells were sonicated and incubated overnight in the dark in 500 μ L
49
50 1M NaOH at 37 °C. Melanin concentrations were calculated by comparison of the OD at 475
51
52 nm of unknown samples with a standard curve obtained with synthetic melanin (Sigma Aldrich,
53
54 St Louis, MO, USA). Melanin content was expressed as pg/cell.
55
56
57
58
59
60

Assay of human tyrosinase activity

The following methods are modifications of protocols adopted from Nagata et al, (Nagata, Takekoshi et al. 2004) and Cheng et al (Cheng, Hsu et al. 2007). Human melanocytes were cultured in 100 mm dishes using medium 254 (Invitrogen, Carlsbad, CA), incubated at 37 °C in a humidified 5% CO₂ chamber. At 80 to 90% confluence, cells were harvested and lysed using 1% Triton X-100 in 0.067 M potassium phosphate buffer (pH 6.8). Cells were then sonicated twice at 20% intensity for 30 sec (on ice). Lysates were clarified by centrifugation at 10,000 g for 10 min. Protein content was determined using a Bio-Rad protein assay kit (Richmond, CA). Lysates were added to a 96 well flat bottom plate containing equal amounts of protein (40µg), and adjusted with lysis buffer to reach 150 µL in each well. L-dopa was dissolved in lysis buffer and added to each well at a final concentration of 2.5 mM. Each triplicate of wells received different concentrations (0 to 2 mM) of oligopeptide or HQ. The plate was incubated at 37 °C for 120 min, and spectrophotometric readings @ 475 nm (Varioskan, Thermo Electron Corporation) were taken at 10 min intervals.

In certain experiments, L-tyrosine was substituted for L-dopa, and used at a final concentration 5 mM in lysis buffer. L-dopa was also added at a final concentration of 0.005% to serve as a co-factor. Several control wells were used in the experiment. Certain wells served as controls and contained 40 µg of protein extract in lysis buffer, and substrate at varying compositions but without peptide inhibitors. Other control wells contained lysis buffer, substrate, peptide inhibitors but no protein extract (no enzyme).

WST assay for Melanocyte proliferation

Melanocyte proliferation was determined using the WST-1 Cell Proliferation Kit (Roche, Palo Alto, CA). Cells were plated at 2.5×10^4 /well in 96-well plates in a humidified atmosphere with

1
2
3 5% CO₂ at 37°C. Twenty-four hours after plating, test samples were added and cultures were
4
5 incubated for an additional 1, 3, or 5 days. Fresh medium and test samples were replaced every
6
7 other day. At the end of the treatment period, 10 µl WST-1 mixture was added to each well
8
9 containing 100 µl fresh medium. The plates were placed at 37°C for 4 h in the dark and the
10
11 absorbance at 450 nm was read using the HTS 7000 Plus Bio Assay reader (Perkin Elmer,
12
13 Waltham, MA). Three replicate wells were measured for each group to be tested. Wells
14
15 containing medium but no cells served as background controls.
16
17
18
19
20
21
22
23
24

25 *Evaluation of the cytotoxic effect of P3, P4 and HQ on melanocytes*

26
27 Melanocytes were cultured in three 6-well plates at a density of 4 x 10⁵ cells/well for either 1, 3,
28
29 or 6 days in 2 ml of medium 254 containing different concentrations of peptides or HQ (0, 10,
30
31 30,100, 300, or 1000 µM). The plates were incubated at 37 °C in a humidified 5% CO₂ chamber.
32
33 Media and inhibitors were changed every 48 hours. After 24 hours, the Plate labeled “Day-1”
34
35 was harvested and cells were counted in each well using a hemacytometer. The control well
36
37 contained 2 ml of media without any inhibitor. The toxicity of the test sample was measured
38
39 according to the following formula:
40
41
42
43
44

$$45 \quad \left[1 - \frac{(\# \text{ of cells in control well}) - (\# \text{ of live cells in test sample well})}{\# \text{ of cells in control well}} \right] \times 100\%$$

46
47
48

49 The same procedure was repeated after 72 hours of incubation for the plate labeled “Day-3” and
50
51 after 144 hours for the “Day-6” plate.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analysis

Each experiment was performed in triplicate and run a minimum of 5 independent times. The results were averaged and standard error of the mean was calculated for all conditions using Microsoft Excel.

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conflict of interest:

There are no conflicts of interest.

For Review Only

1
2
3 **Acknowledgments:**
4

5 There are no acknowledgments.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

References:

- 1
2
3
4
5
6 Briganti, S., E. Camera, et al. (2003). "Chemical and instrumental approaches to treat
7 hyperpigmentation." Pigment Cell Res **16**(2): 101-10.
- 8 Burk, D., H. Lineweaver, et al. (1934). "The Specific Influence of Acidity on the Mechanism of
9 Nitrogen Fixation by Azotobacter." J Bacteriol **27**(4): 325-40.
- 10 Cabanes, J., S. Chazarra, et al. (1994). "Kojic acid, a cosmetic skin whitening agent, is a slow-
11 binding inhibitor of catecholase activity of tyrosinase." J Pharm Pharmacol **46**(12): 982-5.
- 12 Cheng, K. T., F. L. Hsu, et al. (2007). "New constituent from Podocarpus macrophyllus var.
13 macrophyllus shows anti-tyrosinase effect and regulates tyrosinase-related proteins and
14 mRNA in human epidermal melanocytes." Chem Pharm Bull (Tokyo) **55**(5): 757-61.
- 15 Curto, E. V., C. Kwong, et al. (1999). "Inhibitors of mammalian melanocyte tyrosinase: in vitro
16 comparisons of alkyl esters of gentisic acid with other putative inhibitors." Biochem
17 Pharmacol **57**(6): 663-72.
- 18 DeCaprio, A. P. (1999). "The toxicology of hydroquinone--relevance to occupational and
19 environmental exposure." Crit Rev Toxicol **29**(3): 283-330.
- 20 Ennes, S., R. Paschoalick, et al. (2000). "A double-blind, comparative, placebo-controlled study
21 of the efficacy and tolerability of 4 hydroquinone as a depigmenting agent in melasma."
22 Journal of Dermatological Treatment **11**: 173-179.
- 23 Finlay, A. Y. (1997). "Quality of life measurement in dermatology: a practical guide." Br J
24 Dermatol **136**(3): 305-14.
- 25 Hearing, V. J. and T. M. Ekel (1976). "Mammalian tyrosinase. A comparison of tyrosine
26 hydroxylation and melanin formation." Biochem J **157**(3): 549-57.
- 27 Hermanns, J. F., C. Pierard-Franchimont, et al. (2000). "Skin colour assessment in safety testing
28 of cosmetics. An overview." Int J Cosmet Sci **22**(1): 67-71.
- 29 Ishikawa, M., I. Kawase, et al. (2007). "Combination of amino acids reduces pigmentation in
30 B16F0 melanoma cells." Biol Pharm Bull **30**(4): 677-81.
- 31 Jimbow, K., H. Obata, et al. (1974). "Mechanism of depigmentation by hydroquinone." J Invest
32 Dermatol **62**(4): 436-49.
- 33 Johnston, G. A., L. Sviland, et al. (1998). "Melasma of the arms associated with hormone
34 replacement therapy." Br J Dermatol **139**(5): 932.
- 35 Kadekaro, A. L., H. Kanto, et al. (2003). "Significance of the melanocortin 1 receptor in
36 regulating human melanocyte pigmentation, proliferation, and survival." Ann N Y Acad
37 Sci **994**: 359-65.
- 38 Katayama, K., J. Armendariz-Borunda, et al. (1993). "A pentapeptide from type I procollagen
39 promotes extracellular matrix production." J Biol Chem **268**(14): 9941-4.
- 40 Kojima, S., H. Yamaguchi, et al. (1995). "Inhibitory effect of sodium 5,6-benzylidene ascorbate
41 (SBA) on the elevation of melanin biosynthesis induced by ultraviolet-A (UV-A) light in
42 cultured B-16 melanoma cells." Biol Pharm Bull **18**(8): 1076-80.
- 43 Lacz, N. L., J. Vafaie, et al. (2004). "Postinflammatory hyperpigmentation: a common but
44 troubling condition." Int J Dermatol **43**(5): 362-5.
- 45 Lindquist, N. G. (1973). "Accumulation of drugs on melanin." Acta Radiol Diagn (Stockh) **325**:
46 1-92.
- 47 Lupo, M. P. and A. L. Cole (2007). "Cosmeceutical peptides." Dermatol Ther **20**(5): 343-9.
- 48 Lynde, C. B., J. N. Kraft, et al. (2006). "Topical treatments for melasma and postinflammatory
49 hyperpigmentation." Skin Therapy Lett **11**(9): 1-6.
- 50 Maeda, K. and M. Fukuda (1996). "Arbutin: mechanism of its depigmenting action in human
51 melanocyte culture." J Pharmacol Exp Ther **276**(2): 765-9.
- 52 Naeyaert, J. M., M. Eller, et al. (1991). "Pigment content of cultured human melanocytes does
53 not correlate with tyrosinase message level." Br J Dermatol **125**(4): 297-303.
- 54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Nagata, H., S. Takekoshi, et al. (2004). "Quercetin enhances melanogenesis by increasing the activity and synthesis of tyrosinase in human melanoma cells and in normal human melanocytes." *Pigment Cell Res* **17**(1): 66-73.
- Olivares, C., C. Jimenez-Cervantes, et al. (2001). "The 5,6-dihydroxyindole-2-carboxylic acid (DHICA) oxidase activity of human tyrosinase." *Biochem J* **354**(Pt 1): 131-9.
- Palumbo, A., M. d'Ischia, et al. (1991). "Mechanism of inhibition of melanogenesis by hydroquinone." *Biochim Biophys Acta* **1073**(1): 85-90.
- Parvez, S., M. Kang, et al. (2006). "Survey and mechanism of skin depigmenting and lightening agents." *Phytother Res* **20**(11): 921-34.
- Passi, S. and M. Nazzaro-Porro (1981). "Molecular basis of substrate and inhibitory specificity of tyrosinase: phenolic compounds." *Br J Dermatol* **104**(6): 659-65.
- Pathak, M. A., T. B. Fitzpatrick, et al. (1986). "Usefulness of retinoic acid in the treatment of melasma." *J Am Acad Dermatol* **15**(4 Pt 2): 894-9.
- Penney, K. B., C. J. Smith, et al. (1984). "Depigmenting action of hydroquinone depends on disruption of fundamental cell processes." *J Invest Dermatol* **82**(4): 308-10.
- Petit, L. and G. E. Pierard (2003). "Skin-lightening products revisited." *Int J Cosmet Sci* **25**(4): 169-81.
- Piao, L. Z., H. R. Park, et al. (2002). "Mushroom tyrosinase inhibition activity of some chromones." *Chem Pharm Bull (Tokyo)* **50**(3): 309-11.
- Pomerantz, S. H. (1966). "The tyrosine hydroxylase activity of mammalian tyrosinase." *J Biol Chem* **241**(1): 161-8.
- Pomerantz, S. H. and M. C. Warner (1967). "3,4-dihydroxy-L-phenylalanine as the tyrosinase cofactor. Occurrence in melanoma and binding constant." *J Biol Chem* **242**(22): 5308-14.
- Rendon, M., M. Berneburg, et al. (2006). "Treatment of melasma." *J Am Acad Dermatol* **54**(5 Suppl 2): S272-81.
- Robinson, L. R., N. C. Fitzgerald, et al. (2005). "Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin." *Int J Cosmet Sci* **27**(3): 155-60.
- Sanchez-Ferrer, A., J. N. Rodriguez-Lopez, et al. (1995). "Tyrosinase: a comprehensive review of its mechanism." *Biochim Biophys Acta* **1247**(1): 1-11.
- Schallreuter, K. U., S. Kothari, et al. (2008). "Regulation of melanogenesis--controversies and new concepts." *Exp Dermatol* **17**(5): 395-404.
- Schallreuter, K. U. and J. W. Wood (1990). "A possible mechanism of action for azelaic acid in the human epidermis." *Arch Dermatol Res* **282**(3): 168-71.
- Schurink, M., W. J. van Berkel, et al. (2007). "Novel peptides with tyrosinase inhibitory activity." *Peptides* **28**(3): 485-95.
- Solano, F., S. Briganti, et al. (2006). "Hypopigmenting agents: an updated review on biological, chemical and clinical aspects." *Pigment Cell Res* **19**(6): 550-71.
- Sugimoto, K., T. Nishimura, et al. (2003). "Syntheses of arbutin-alpha-glycosides and a comparison of their inhibitory effects with those of alpha-arbutin and arbutin on human tyrosinase." *Chem Pharm Bull (Tokyo)* **51**(7): 798-801.

Table 1. Oligopeptide inhibitory profile against mushroom tyrosinase

Oligopeptide	Sequence	IC ₅₀ [M] ¹
P1	SFLLRN	8 mM
P2	KFEKKFEK	3.6 mM
P3	RADSRADC	123 μM
P4	YRSRKYSSWY	40 μM
P5	PLG	2.73 mM
P6	VLLK	No effect
P7	KFEFKFEF	No effect

¹ IC₅₀ [M] = concentration at 50% inhibition of mushroom tyrosinase in molar.

Table 2. The toxic effect of HQ, P3, and P4.

Concentration	% Cell Death ¹								
	Day 1			Day 3			Day 6		
[μ M]	P3	P4	HQ	P3	P4	HQ	P3	P4	HQ
1	0	2	10	0	3	12	0	3	10
10	0	3	27	0	6	29	0	5	48
30	0	3	41	0	4	53	0	5	76
100	0	4	98	0	4	100	0	7	100
300	0	6	100	0	11	100	1	9	100
1000	0	10	100	0	15	100	2	18	100

¹ Human melanocytes were incubated with HQ, P3 and P4 at the above concentrations for 1, 3 and 6 days. The assay was carried out in triplicates, and the percent cell death was calculated according to the formula discussed in the methods section.

Figure Legends:**Figure 1:**

Dose response curves for all seven peptides and HQ were taken at 120 min post-incubation with varying concentrations. The experiment was conducted in a 96-well flat bottom plate. Each well contained 80 μ l of 0.067 M potassium phosphate buffer (pH 6.8), 40 μ l of 5 mg/ml L-tyrosine dissolved in 0.067 M potassium phosphate buffer (pH 6.8), 40 μ l of the different concentrations of inhibitor in 5% DMSO solution, and 40 μ l of 480 units/ml mushroom tyrosinase solution. The assay mixture was incubated at 37 °C and spectrophotometric readings @ 475nm were taken every 10 mins.

(a) P1, P2, P5, P6 and P7. (b) HQ, P3 and P4.

Figure 2:

Time response curves for peptides P3 and P4 along with the control HQ. The final volume of each well was 200 μ l, containing 1 mg/ml L-tyrosine, 96 units/ml of mushroom tyrosinase and varying concentrations of inhibitors, ranging from 10 μ M to 10 mM. The 96-well plate was incubated @37°C and the spectrophotometric readings taken every 10 mins. Each point on the graph is an average of five independent trials, displayed with error bars.

(a) P3. (b) P4. (c) HQ.

Figure 3:

Lineweaver-Burk plots. (a) P3 (b) P4 and (c) HQ. The concentration of mushroom tyrosinase [E] was 24 units/ml. The series of substrate [S] were 0.05 (or 0.07 for peptide inhibitors), 0.1, 0.15 and 0.2 mg/ml. The series of inhibitor [I] were 0, 0.01 and 0.02 mM, respectively. The results were analyzed according to the Lineweaver-Burk plot method that allows the determination of the Michaelis constant (Km) and maximum velocity (Vm). All inhibitors showed competitive inhibition pattern.

Figure 4:

Dose response curves with human tyrosinase. Melanocytes were lysed using 1% Triton X-100 in 0.067 M potassium phosphate buffer (pH 6.8). Cells were then sonicated twice at 20% intensity for 30 sec. Lysates were clarified by centrifugation at 10,000 g for 10 min. after measuring protein content, an equal amount of 40 μ g was added to each well and adjusted with lysis buffer to reach 150 μ L. Each triplicate of wells received different concentrations (0 to 2 mM) of oligopeptide or HQ.

(a) Using L-dopa as the substrate. L-dopa was dissolved in lysis buffer and added to each well at a final concentration of 2.5 mM. The plate was incubated at 37 °C for 120 min, and spectrophotometric readings @ 475 nm were taken at 10 min intervals.

(b) Using L-tyrosine as substrate with L-dopa at a final concentration of 0.005% as a co-factor.

Figure 5:

The effects of peptides and HQ on the melanin content of melanocytes, expressed in pg/cell. The tested concentrations were 1, 10 and 100 μ M. Melanocytes were incubated with test samples for a week. Cells were lysed and incubated O/N in 1M NaOH. Melanin content was determined by comparing the absorbance results with a standard curve generated from synthetic melanin

Figure 6:

Proliferation of human melanocytes treated with HQ, P3, and P4. 25,000 human melanocytes per well were incubated at 37°C in the presence of 10, 100, 1000 μ M HQ, P3 and P4 in medium 254 for 1, 3, 5 days. After the incubation 10 μ l WST-1 was added to each well and absorbance was read at 450 nm after four hour incubation at 37°C.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49




Figure 1






Figure 2




Figure 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49




Figure 5




Figure 6